Effect of Activating and Inactivating Mutations on the Phosphorylation and Trafficking of the Human Lutropin/Choriogonadotropin Receptor
Le Min and
Mario Ascoli
Department of Pharmacology The University of Iowa College of
Medicine Iowa City, Iowa 52242-1109
 |
ABSTRACT
|
---|
The effects of several mutations of the human LH
receptor (hLHR) on the phosphorylation, internalization, and turnover
of the cell surface receptor were examined. Three gain-of-function
mutations associated with Leydig cell hyperplasia (L457R and D578Y) and
one associated with Leydig cell adenomas (D578H), one
signaling-impaired mutation associated with Leydig cell hypoplasia
(I625K), and two laboratory designed signaling-impaired mutations
(D405N and Y546F) were used. The signaling-impaired mutations showed a
reduction in human CG (hCG)-induced receptor phosphorylation and
internalization. Mutation of the phosphorylation sites of these
loss-of-function mutants had little or no additional effect on
internalization. Cotransfection with G protein-coupled receptor
kinase-2 (GRK2) rescued the hCG-induced phosphorylation and
internalization of the signaling-impaired mutations but only if the
phosphorylation sites were intact. Overexpression of arrestin-3 rescued
the rate of internalization regardless of whether or not the
phosphorylation sites were intact.
Only two of the three constitutively active mutants displayed an
increase in basal phosphorylation. Although they all failed to respond
to hCG with increased receptor phosphorylation, they all internalized
hCG faster than wild-type hLHR (hLHR-wt). Mutation of the
phosphorylation sites of these constitutively active mutants lengthened
the half-time of internalization of hCG toward that of hLHR-wt.
Overexpression of arrestin-3 had little or no effect on the already
short half-time of internalization of hCG mediated by these mutants.
The data obtained with the signaling-impaired and
phosphorylation-deficient mutants of the hLHR support a model whereby
receptor phosphorylation and activation play a redundant role in the
internalization of hCG. The results obtained with the constitutively
active mutants suggest that, when occupied by hCG, these mutants assume
a conformation that bypasses many of the steps (i.e.
activation, phosphorylation, and/or arrestin binding) involved in
internalization.
 |
INTRODUCTION
|
---|
Previous studies have shown that, like many other G
protein-coupled receptors (GPCRs), the binding of agonist to the rat LH
receptor (rLHR) leads to the phosphorylation of the receptor (1) and
that this process facilitates the internalization of the agonist-rLHR
complex (2, 3) via clathrin-coated pits by a pathway that requires the
participation of clathrin, a nonvisual arrestin and dynamin (3, 4, 5, 6). In
agreement with this model, it has also been shown that activating
mutations of the rLHR enhance the internalization of hCG whereas
phosphorylation-deficient or inactivating mutations of the rLHR impair
the internalization of hCG (2, 3, 7, 8, 9).
Since GPCR activation is an important determinant of the
agonist-induced GPCR phosphorylation (reviewed in Refs. 10, 11), the
effects of activating and inactivating mutations of the rLHR on the
internalization of hCG could be directly due to the effects of these
mutations on receptor activation or they could be more indirectly
mediated by changes in receptor phosphorylation. This question has been
difficult to address with the rLHR because the level of expression of
the rLHR in transiently transfected cells is rather low. Although this
low level of transient expression does not affect our ability to
conduct internalization assays (3, 5, 6), the phosphorylation of the
rLHR can only be studied in stably transfected cells (1, 2, 3, 12, 13).
Thus, structure-function studies on the phosphorylation of the rLHR are
very laborious because stably transfected cell lines with matched
receptor numbers (at least
100,000 receptors per cell) must be
prepared for each mutant to be analyzed (2, 3, 12, 13). In addition,
the use of cotransfection strategies that are helpful in understanding
receptor phosphorylation and internalization cannot be readily
accomplished using stably transfected cell lines.
In recent comparative studies on the human LH receptor (hLHR) and the
rat LH receptor we noticed that the level of expression of the hLHR is
much higher than that of the rLHR (
40,000 and
400,000 receptors
per cell, respectively) in 293 cells transiently transfected with
optimal amounts of plasmid. Since these high levels of expression of
the hLHR allow for the quantitation of receptor phosphorylation in
transiently transfected cells, we reasoned that this experimental
system would be more amenable to structure-function studies designed to
address the involvement of receptor activation and phosphorylation in
the process of internalization. In the studies presented herein we took
advantage of these properties of the hLHR and analyzed several
mutants of the hLHR to better understand the importance of receptor
activation and phosphorylation in the trafficking of the hLHR.
 |
RESULTS
|
---|
Signaling Properties of hLHR Mutants
Three naturally occurring activating mutations of the hLHR, L457R,
D578Y, and D578H, were chosen for these studies. The L457R and D578Y
mutations are germ-line mutations that were initially found in boys
with male-limited, gonadotropin-independent precocious puberty (14, 15). These point mutations are located in transmembrane helix 3 (TM3)
and TM6, respectively. The D578H mutation of the hLHR is a somatic
mutation that was recently identified in Leydig cell adenomas of three
boys exhibiting precocious puberty (16). Heterologous cells expressing
any of these three mutants display an elevated level of cAMP in the
absence of agonist stimulation but respond to further agonist
stimulation with a minimal increase or with no increase in cAMP
accumulation (14, 16, 17).
Since many of the experiments described below necessitate robust
surface expression, our choice of naturally occurring mutations that
impair signaling was severely limited by the finding that many of these
mutants are usually characterized by decreased expression and/or proper
plasma membrane localization. We eventually settled on a point mutation
in TM7 (I625K) that reduces cell surface expression only by
approximately 50% (18). This mutant was initially identified in three
brothers with a mild form of Leydig cell hypoplasia (18). When compared
with cells expressing the wild-type hLHR (hLHR-wt), the agonist-induced
cAMP response of cells expressing the I625K mutation (measured
indirectly as an increase in the expression of a cAMP-driven reporter
gene) is characterized by a rightward shift in the
EC50 and a reduction in the maximal response.
Because it is important to examine mutations that impair signaling, we
also chose to analyze two laboratory-designed hLHR mutations (D405N in
TM2 and Y546F in TM5) that, based on equivalent mutations of other
GPCRs (7, 8, 19, 20, 21, 22), were predicted to result in an impairment in
agonist-induced activation of the hLHR without affecting surface
expression.
One additional mutant (designated 5S/A), in which five serine residues
in the C-terminal tail of the hLHR (residues 657, 661, 670, 674, and
676) were simultaneously mutated to alanines, was constructed and
analyzed. This mutant was predicted to be phosphorylation deficient
based on the knowledge that four equivalent serines of the rLHR
(residues 635, 639, 649, and 652) become phosphorylated upon agonist
stimulation (2, 3, 12).1
Although the signaling properties of some of the hLHR mutants described
above have been previously characterized (14, 16, 17, 18), it was important
to document these properties under our experimental conditions. This
was done by measuring cAMP accumulation in transiently transfected 293
cells incubated with increasing concentrations of hCG. For simplicity,
however, the data presented in Table 1
summarize only the response obtained
with a concentration of hCG (3 nM) chosen to elicit maximal
cAMP accumulation in cells expressing hLHR-wt (c.f. Fig. 1
). To correct for the inherent
variability associated with measuring the cAMP responses of transiently
transfected cells, the basal and hCG-induced cAMP responses mediated by
the different mutants were corrected by normalization to the cholera
toxin-induced cAMP response measured in the same experiment (see
columns labeled "Basal/Cholera Toxin" and "hCG/Cholera Toxin"
in Table 1
). Thus, instead of using the absolute levels of cAMP, the
responsiveness of cells expressing the different mutants shown in Table 1
should be compared by using these ratios. Lastly, all cells were also
tested for 125I-hCG binding to ensure that
variations in signaling were not due to variations in receptor
expression. Table 1
shows that the cell surface expression of all
activating mutations (L457R, D578Y, and D578H) is comparable to that of
hLHR-wt. When incubated in the absence of agonist, the basal levels of
cAMP detected in cells expressing the three activating mutations are
15- to 30-fold higher than those detected in cells expressing an
equivalent density of hLHR-wt (see "Basal/Cholera Toxin" in Table 1
). These elevated levels of basal cAMP account for 2550% of the
amount of cAMP produced when cells expressing an equivalent density
hLHR-wt are stimulated with a maximally effective concentration of hCG.
A comparison of the hCG/cholera toxin ratio to the basal/cholera toxin
ratio in Table 1
shows that the cells expressing the activating mutants
respond poorly to hCG stimulation (D578Y) or not at all (L457R or
D578H). Full dose-response curves for cells expressing these mutants
have been published by others (14, 16, 17) and are in general agreement
with the data shown in Table 1
.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 1. Representative Dose-Response Curves for the
hCG-Induced cAMP Accumulation of Cells Transiently Transfected with the
Laboratory-Designed Inactivating Mutations of the hLHR
293 cells plated in 35-mm wells were transiently transfected with
hLHR-wt (squares), hLHR-D405N
(triangles), or hLHR-Y546F (circles), and
dose-response curves for the hCG-induced cAMP accumulation were
performed and analyzed as described in Materials and
Methods. The results of a representative experiment using
duplicate wells for each concentration of hCG are shown. The
EC50s for hCG were 0.1, 1.3, and 2.9 nM, and
the maximal hCG responses were 3,900, 3,000, and 2,800
pmol/106 cells in the cells transfected with the hLHR-wt,
-D405N, or -Y546F, respectively. 125I-hCG binding was 676,
611, and 689 fmol/106 cells, and the responses to 0.6
nM cholera toxin were 1,424, 1,420, and 1,304 pmol
cAMP/106 cells in the cells transfected with the hLHR-wt,
-D405N, or -Y546F, respectively. The vertical dashed
line shows the concentration of hCG used in the experiments
summarized in Table 1 .
|
|
The cell surface expression of the two laboratory-designed mutations
that are predicted to impair signaling (D405N and Y546F) are also
comparable to that of hLHR-wt. The hCG/cholera toxin ratios summarized
in Table 1
show that cells expressing these mutants display a reduced
cAMP responsiveness to a concentration of hCG (3 nM) that
is maximally effective in cells expressing hLHR-wt. The representative
dose- response curves presented in Fig. 1
show that this reduction
is due mostly to an approximately 10- to 30-fold increase in the
EC50 for hCG displayed by cells expressing the
D405N or Y546F mutants. The maximal hCG-induced cAMP response of cells
expressing the D405N or Y546F mutants were only approximately 15 to
25% lower that those expressing a comparable density of hLHR-wt (Fig. 1
). Cells expressing the naturally occurring mutation that impairs
signaling (I625K) show an approximately 2-fold decrease in surface
expression compared with cells expressing hLHR-wt as expected from
published results (18). The reduced cAMP responsiveness to 3
nM hCG shown by the hCG/cholera toxin ratio in Table 1
for
cells expressing the I625K mutant is a reflection of a reduction in the
maximal response and an increase in the EC50 as
previously documented by other investigators (18). Although this
reduced hCG response mediated by the I625K mutant should be interpreted
with some caution (because of its reduced surface expression, see Table 1
), we do not think that it can be solely explained by reduced surface
expression because at these levels of receptor expression a 2- to
5-fold decrease in the expression of hLHR-wt has little or no effect on
basal or hCG-stimulated cAMP accumulation (data not shown). Lastly, the
basal cAMP and hCG-induced cAMP responses (as judged by the response
ratios shown in Table 1
) mediated by the 5S/A mutant were
indistinguishable from those of cells expressing a comparable density
of hLHR-wt.
Phosphorylation of hLHR Mutants
After labeling with 32P-orthophosphate,
transiently transfected cells expressing the different mutants were
stimulated with maximally effective concentrations of hCG or PMA for 15
min at 37 C. Since the concentrations of hCG needed to induce
phosphorylation of the LHR closely resemble those needed for receptor
occupancy, we used a saturating concentration of hCG (26
nM) in an attempt to fully saturate the receptors and
optimize the phosphorylation signal during the short incubation period
used [the dissociation constant (Kd) for hCG
binding to the hLHR is 13 nM, see Ref. 6 ]. Stimulation
of 293 cells stably expressing the rLHR-wt with 200 nM PMA
has been previously shown to result in robust phosphorylation of rLHR
(1), and it was included here as a positive control. Cell lysates were
prepared, equalized for receptor expression (based on parallel binding
assays performed in intact cells), immunoprecipitated with the 9E10
antibody, resolved on SDS gels, and visualized and quantitated with a
PhosphorImager as described in Materials and Methods.
Stimulation of cells expressing hLHR-wt with hCG or PMA results in an
approximately 3- and 4-fold increase in the incorporation of
32P into the receptor, respectively (Figs. 2
and 3
).
In general agreement with our analysis of phosphorylation sites of the
rLHR (2, 3, 12), we found that the simultaneous mutation of five serine
residues clustered toward the C-terminal end of the hLHR (a mutant
designated 5S/A) results in undetectable basal phosphorylation, an
approximately 90% inhibition of phosphorylation induced by hCG, and a
7080% inhibition of the PMA-induced phosphorylation (Figs. 2
and 3
).
Thus, we can readily conclude that most of the hCG-induced
phosphorylation of the hLHR occurs in one or more of these five
residues. We can also conclude that the sites phosphorylated in
response to PMA or hCG stimulation are overlapping but not
identical.

View larger version (43K):
[in this window]
[in a new window]
|
Figure 2. Phosphorylation of hLHR Mutants
293 cells plated in 100-mm dishes were transiently transfected with the
indicated constructs to give equivalent expression of cell surface
receptor as described in Table 1 . The cells were labeled with
32P-orthophosphate for 3 h at 37 C and further
incubated for 15 min with buffer only, 26 nM hCG, or 200
nM PMA at 37 C as indicated. Lysates were prepared and
aliquots containing identical amounts of cell surface receptor were
partially purified on a wheat germ agglutinin column and
immunoprecipitated as described in Materials and
Methods. The immunoprecipitates were resolved on SDS gels, and
the radiolabeled bands were detected and captured in a digital format
using a PhosphorImager. The results of a representative experiment
displaying only the relevant portions of the gels are presented. The
intensity of the bands should be compared only within each panel. They
should not be compared among the different panels because we did not
attempt to maintain constant exposure conditions.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Figure 3. Quantitative Assessment of the Phosphorylation of
hLHR Mutants
293 cells plated in 100-mm dishes were transiently transfected with the
indicated constructs to give equivalent expression of cell surface
receptor as described in Table 1 . The cells were labeled with
32P-orthophosphate for 3 h at 37 C and further
incubated for 15 min with buffer only, 26 nM hCG, or 200
nM PMA at 37 C as indicated. Lysates were prepared and
identical amounts of cell surface receptor were analyzed exactly as
described in the legend to Fig. 2 . Each experiment included cells
expressing the hLHR-wt that were incubated with buffer only and a
maximum of six additional dishes consisting of two sets of transiently
transfected cells (each expressing a different receptor construct and
incubated with buffer only, hCG, or PMA). The magnitude of the
phosphorylation signal measured in the two sets of cells was expressed
as fold over the basal phosphorylation of the hLHR-wt included in the
same experiment. Each bar represents the mean ±
SEM of at least four independent transfections. a,
Statistically different (P < 0.05) from wt basal.
b, Statistically different (P < 0.05) from its own
basal.
|
|
Cells expressing two of the three activating mutations (L457R and
D578H) displayed an approximately 2-fold increase in
agonist-independent receptor phosphorylation but the
agonist-independent phosphorylation of the third activating mutation
(D578Y) was not increased (compare the white bars for the
activating mutations with the white bar for the
hLHR-wt in Fig. 3
). The addition of hCG to cells expressing
any of these activating mutations resulted in little or no additional
hLHR phosphorylation over that detected in the basal state (compare the
shaded and white bars shown for each mutant in
Fig. 3
). The impairment in the ability of hCG to enhance the
phosphorylation of the L457R, -D578Y, and D578H mutants parallels the
impairment in the hCG-induced cAMP response detected in cells
expressing these mutants (c.f. Table 1
). Lastly, the addition of PMA to
cells expressing the L457R and D578Y mutants led to an increase in
receptor phosphorylation over that seen in the basal state (compare the
black and white bars shown for each mutant in Fig. 3
), but
cells expressing D578H failed to respond to PMA with an additional
increase in phosphorylation above that detected in the basal state. The
lack of correlation between constitutive activation and increased basal
phosphorylation of the L457R, D578Y, and D578H mutants of the hLHR
(Figs. 2
and 3
) agrees with recent findings reported for other GPCRs.
For example, constitutively active mutants of the
1b- adrenergic
(24) or the angiotensin II type 1 receptor (25) do not uniformly
display an increase in agonist-independent phosphorylation. In
addition, agonist binding fails to enhance the phosphorylation of some
constitutively active mutants of these two GPCRs (24, 25).
As shown above, the magnitude of the effect of hCG on receptor
phosphorylation is not particularly strong, and phosphorylation assays
done in transiently transfected cells require robust expression of the
different receptor constructs. Unfortunately, the relatively low levels
of expression of the signaling-impaired I625K mutant (c.f. Table 1
)
precluded the use of this mutant in phosphorylation experiments.
Therefore, the potential effects of signaling-impaired mutations on
receptor phosphorylation could only be analyzed with the two
laboratory-designed mutations that impair signaling (D405N and Y546F).
Cells expressing these mutants displayed normal levels of
agonist-independent receptor phosphorylation and an impairment in
hCG-induced phosphorylation (compare the shaded and
white bars shown for each mutant in Fig. 3
) that paralleled
the impairment in their ability to mediate a cAMP response (Table 1
).
Lastly, PMA was still able to enhance the phosphorylation of cells
expressing any of the inactivating mutations (compare the
black and white bars for each mutant in Fig. 3
).
Overall then, the properties of the basal and hCG-dependent
phosphorylation of these mutations seem to parallel their activation
properties (as measured by cAMP accumulation and shown in Table 1
).
Agonist-Induced Internalization of hLHR Mutants
Since the methods used to measure the t1/2
of internalization are rather sensitive (see Materials and
Methods) and this parameter is not dependent on the density of
cell surface receptors (26), the t1/2 values of
internalization of hCG could be reliably measured in cells expressing
any of the seven mutants described above.
The data summarized in Table 2
show that
cells expressing the three activating mutations (L457R, D578Y, and
D578H) internalize hCG with half-times that are 3- to 7-fold shorter
than that measured in cells expressing hLHR-wt. Cells expressing the
three signaling-impaired mutations (D405N, Y546F, and I625K)
internalize hCG with half-times that are 5- to 7-fold longer than those
measured in cells expressing hLHR-wt. Mutation of the phosphorylation
sites of the hLHR (5S/A) lengthened the t1/2 of
internalization of hCG less than 2-fold.
Dynamin-K44A is a GTPase-deficient mutant of dynamin that behaves as a
dominant-negative mutant and inhibits the internalization of many
GPCRs, including the rLHR and hLHR (3, 5, 6, 27, 28, 29, 30). Overexpression of
this construct lengthened the t1/2 of
internalization of hCG mediated by the hLHR-wt and all mutants (Table 2
). Arrestin-3(284409), is a construct that encodes for the
clathrin-binding domain of arrestin-3 and behaves as a
dominant-negative inhibitor of nonvisual arrestin-mediated endocytosis
(31). Overexpression of this construct also lengthened the
t1/2 of internalization of hCG mediated by
hLHR-wt, -5S/A, and all three activating mutants but had only a small
effect on the already long t1/2 of
internalization of hCG mediated by the signaling-impaired mutations
(Table 2
). It should also be noted that, in spite of the inhibitory
effects of arrestin-2(284309) on the t1/2 of
internalization of hCG mediated by any of the activating mutations of
the hLHR, the t1/2 of internalization of hCG
measured in cells cotransfected with the activating mutants of the hLHR
and arrestin-3(284409) was similar (i.e. 1131 min) to
that detected in cells cotransfected with hLHR-wt and an empty vector
(i.e.
20 min). Conversely, arrestin-3 shortened the
t1/2 of internalization of hCG mediated by
hLHR-wt, -5S/A, and all three signaling-impaired mutations but had
little or no effect on the already short t1/2 of
internalization of hCG mediated by the activating mutations. The
effects of arrestin-3 on the inactivating mutations were rather
pronounced, and the t1/2 of internalization of
hCG in cells co-transfected with the D405N, Y546F, or I625K mutants and
arrestin-3 (i.e. 818 min) was similar to that detected in
cells cotransfected with hLHR-wt and an empty vector (
20 min).
Since the D405N, Y546F, and I625K mutations impair receptor
activation2 (Table 1
), phosphorylation
(Figs. 2
and 3
), and agonist internalization (Table 2
), we cannot
determine whether the impairment in internalization is due to the
impairment in receptor activation or in the phosphorylation of the
receptor. This is an important issue because the involvement of hLHR
phosphorylation on internalization appears to be minimal as documented
by the finding that the internalization of hCG is barely affected by
mutation of five serine residues in the C-terminal tail of the hLHR
(i.e. the 5S/A mutant in Table 2
) that drastically impair
phosphorylation (Figs. 2
and 3
) without impairing receptor activation
(Table 1
). An independent assessment of the relative importance of
activation and phosphorylation in internalization was conducted by
analyzing double mutants in which the phosphorylation sites of the
D405N, Y546F, and I625K mutants were simultaneously mutated to alanine
residues. Since the phosphorylation of signaling-impaired mutants can
often be rescued by overexpression of one of the G protein-coupled
receptor kinases (GRKs) (22, 33), we also analyzed the behavior of
these mutants in cells cotransfected with GRK2.
The data presented in Fig. 4
show that
cotransfection with GRK2 enhances the hCG-promoted
phosphorylation3 of the hLHR-wt, and it
rescues the impairment in hCG-promoted phosphorylation displayed by the
D405N and Y546F mutants. Figure 4
also shows that mutation of the
phosphorylation sites of hLHR-wt, hLHR-D405N, and
hLHR-Y546F4 largely prevents
phosphorylation even in cells cotransfected with GRK2. The results
summarized in Fig. 5
show that 1)
mutation of the phosphorylation sites of hLHR-D405N, -Y546F, and
-I625K5 had no measurable
effect on the already slow t1/2 of
internalization of hCG mediated by these mutants (compare white
bars in the left and right panels of Fig. 5
); 2) overexpression of GRK2 shortens the t1/2
of internalization of hCG mediated by D405N, Y546F, and I625K (compare
white and black bars on the left panel
of Fig. 5
) to levels that are similar to those detected in cells
expressing hLHR-wt; and 3) mutation of the phosphorylation sites of
hLHR-D405N, -Y546F, and -I625K prevents the ability of GRK2 to rescue
the slow rate of internalization of hCG mediated by these mutants
(compare the white and black bars on the
right panel of Fig. 5
).

View larger version (35K):
[in this window]
[in a new window]
|
Figure 4. Effects of GRK2 Cotransfection on the hCG-Induced
Phosphorylation of hLHR-wt and Mutants Thereof
293 cells plated in 100-mm dishes were transiently transfected with the
indicated constructs to give equivalent expression of cell surface
receptor as described in Table 1 . Wt-S/A, D405N-S/A, and Y546F-S/A
denote constructs encoding for the wt, D405N, and Y546F receptors where
Ser657, Ser661, Ser670,
Ser674, and Ser676 were simultaneously mutated
to alanine residues. Lanes labeled +GRK2 and -GRK2 are from cells that
were cotransfected with the indicated receptor construct and 2 µg of
GRK2 or pcDNA3.1, respectively. The amount of GRK2 transfected was
optimized based on its effects on the hCG-induced phosphorylation of
the hLHR-wt. The expression of the protein encoded by these constructs
has been previously documented by Western blotting (34 39 ). The
transiently transfected cells were labeled with
32P-orthophosphate for 3 h at 37 C and further
incubated for 15 min with buffer only or 26 nM hCG at 37 C
as indicated. Lysates were prepared, and identical amounts of cell
surface receptor were immunoprecipitated without lectin purification as
described in Materials and Methods. The
immunoprecipitates were resolved on SDS gels and the radiolabeled bands
were detected and captured in a digital format using a PhosphorImager.
The results of a representative experiment displaying only the relevant
portions of the gels are presented. The intensity of the bands should
be compared only within each panel. They should not be compared among
the different panels because we did not attempt to maintain constant
exposure conditions.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Figure 5. Effects of GRK2 Cotransfection on the Rates of
Internalization of 125I-hCG Mediated by Inactivating
Mutations of the hLHR
293 cells plated in 35-mm wells were transiently transfected with the
indicated constructs, and the t1/2 of internalization of
125I-hCG was measured as described in Materials and
Methods. The amount of hLHR constructs used (0.2 µg/well) was
chosen to give equivalent expression of cell surface receptor as shown
in Table 1 . Columns labeled GRK2 and pcDNA3.1 are from cells that were
cotransfected with the indicated receptor constructs and 0.2 µg of
GRK2 or pcDNA3.1, respectively (also see legend to Fig. 4 ). The
receptor constructs used in the right panel are the same
as those used in the left panel except that those used
in the right panel also had Ser657,
Ser661, Ser670, Ser674, and
Ser676 simultaneously mutated to alanine residues. Each
bar represents the mean ± SEM of at
least three independent transfections. The absence of an error
bar indicates that the SEM is too small to be
shown. a, Statistically different (P < 0.05) from
cells cotransfected with pcDNA3.1.
|
|
To complement these data, we also rendered the activating mutations
(i.e. L457R, D578Y, and D578H) phosphorylation deficient by
mutation of their phosphorylation sites and examined the
internalization of hCG mediated by these double mutants. Figure 6
shows that mutation of the
phosphorylation sites of hLHR-L435R, -D578Y, and -D578H lengthens the
t1/2 of internalization of hCG approximately
3-fold, bringing it to values that are comparable to the
t1/2 of internalization mediated by hLHR-wt.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 6. Rates of Internalization of 125I-hCG
Mediated by Activating Mutations of the hLHR
293 cells were transiently transfected with the indicated constructs,
and the t1/2 of internalization of 125I-hCG was
measured as described in Materials and Methods. The
amounts of hLHR constructs used (0.2 µg/well) were chosen to give
equivalent expression of cell surface receptor as shown in Table 1 . The
receptor constructs denoted by the black bars are the
same as those denoted by the white bars, except that
those denoted by the black bars also had
Ser657, Ser661, Ser670,
Ser674, and Ser676 simultaneously mutated to
alanine residues. Each bar represents the mean ±
SEM of at least three independent transfections. a,
Statistically different (P < 0.05) from mutant
with intact phosphorylation sites.
|
|
Agonist-Independent Turnover of hLHR Mutants
The last series of experiments were designed to ascertain the
effect of the mutations described above on the turnover of the cell
surface hLHR in cells that had not been exposed to agonist. This goal
was accomplished by following the fate of the hLHR after
bio-tinylation of the cell surface proteins (35, 36). As shown in
Fig. 7A
, streptavidin blots of 9E10
immunoprecipitates of lysates obtained from biotinylated cells result
in the visualization of a prominent (
85 kDa) band that is present in
293 cells transfected with hLHR-wt but absent from untransfected cells
or from cells transfected with the empty expression vector. This band
represents the mature, cell surface LHR as shown previously (37, 38).

View larger version (30K):
[in this window]
[in a new window]
|
Figure 7. Biotinylation of the Cell Surface hLHR and Mutants
Thereof
Panel A, 293 cells were transiently transfected with hLHR-wt or
pcDNA3.1 or left untransfected as indicated. The cell surface proteins
were covalently modified with biotin, and lysates were prepared,
immunoprecipitated with the 9E10 antibody, and resolved on SDS gels.
After electrophoretic blotting the biotinylated proteins were
visualized using horseradish peroxidase-labeled streptavidin and the
enhanced chemiluminescence (ECL) system as described in
Materials and Methods. The results of a representative
experiment are shown. Panel B, 293 cells were transiently transfected
with the indicated constructs. The cell surface proteins were
biotinylated, and the biotinylated proteins immunoprecipitated by the
9E10 antibody were detected as described above immediately after
biotinylation (t = 0) or after a 4-h incubation of biotinylated
cells at 37 C. The results of a representative experiment displaying
only the relevant portion of the blot are shown.
|
|
Cells transfected with each of the mutants described above were then
biotinylated and processed immediately after biotinylation or at the
end of a 4-h incubation at 37 C in the absence of agonist. Cell lysates
were prepared and the levels of biotinylated cell surface LHR were
quantitated using streptavidin overlays of 9E10 immunoprecipitates as
described in Materials and Methods. The results of a
representative experiment showing only the appropriate areas of the
blots are shown in Fig. 7B
and the quantitation of several experiments
is shown in Fig. 8
. During the 4-h
incubation period used here, there is little or no change in the
complement of surface LHR in cells expressing the hLHR-wt or the 5S/A
mutant. The density of surface receptors in cells expressing the three
activating mutations decreased by 2575% during the same time period,
whereas the density of surface receptors in cells expressing the
signaling-impaired mutations decreased by 1040%. Thus, the faster
turnover of the L435R, D578Y, and D578H mutants is not a property
uniquely associated with constitutive activation.

View larger version (38K):
[in this window]
[in a new window]
|
Figure 8. Agonist-Independent Turnover of the Cell Surface
hLHR and Mutants Thereof
293 cells were transiently transfected with the indicated constructs to
give equivalent expression of cell surface receptor as shown in Table 1 . The cell surface proteins were biotinylated, the cells were lysed,
and the lysates were immunoprecipitated with the 9E10 antibody. The
immunoprecipitates were resolved on SDS gels, and the biotinylated
proteins were detected as described in the legend to Fig. 6 (also see
Materials and Methods). Immunoprecipitates were prepared
and analyzed immediately after biotinylation (t = 0) or after a
4-h incubation of biotinylated cells at 37 C. The ECL signal from the
blots was visualized and quantitated using a Fluo-S MAX system
(Bio-Rad Laboratories, Inc.). For each construct the
signal detected at t = 4 h was expressed as % of the signal
detected at t = 0 h. Each bar represents the
mean ± SEM of at least three independent
transfections. a, Statistically different (P <
0.05) from cells expressing hLHR-wt.
|
|
 |
DISCUSSION
|
---|
Our laboratory has previously conducted extensive experiments on
the internalization of hCG mediated by the rLHR and mutants thereof,
and such studies reveal many interesting similarities with those
reported here with the hLHR. The first similarity is that the receptor
residues that are phosphorylated in response to agonist stimulation
appear to be fairly conserved between the hLHR and the rLHR. Thus, the
mutation of equivalent (see footnote 1) serine residues in the
C-terminal tail of these two receptors (Ser635,
Ser639, Ser649, and
Ser652 in the rLHR and
Ser657, Ser661,
Ser670, Ser674, and
Ser676 in the hLHR) largely prevents agonist-
induced phosphorylation (
Figs. 24

and Ref. 2). Second, the
mutation of these phosphorylation sites lengthens the
t1/2 of internalization of hCG mediated by the
hLHR or the rLHR 1.5- to 2.5-fold (Table 2
and Refs. 2, 3). It
should be noted that although the magnitude of this change is roughly
the same, the absolute value of the t1/2 of
internalization of the phosphorylation-deficient mutant of the rLHR is
approximately 10 times longer than that of the equivalent mutant of the
hLHR simply because the t1/2 of internalization
of the rLHR-wt is also several fold longer than that of the hLHR-wt
(6). Third, equivalent mutations of the hLHR (D405N in TM3 and Y546F in
TM6) and the rLHR (D383N in TM3 and Y524F in TM6) that impair
agonist-induced activation of the receptor lengthen the
t1/2 of internalization of hCG (Tables 1
and 2
and Refs. 7, 8), whereas equivalent mutations of the hLHR (L435R in
TM3 and D578Y in TM6) and the rLHR (L435R in TM3 and D556Y in TM6) that
induce agonist-independent receptor activation shorten the
t1/2 of internalization of hCG (Tables 1
and 2
and Refs. 8, 9). Fourth, overexpression of a dominant-negative
mutants of dynamin or a dominant-negative mutant of the nonvisual
arrestins lengthen the t1/2 of
internalization of hCG mediated by the hLHR and the rLHR (Table 2
and
Refs. 3, 5, 6), whereas overexpression of the nonvisual arrestins
shortens the t1/2 of internalization of hCG
mediated by the hLHR and the rLHR (Table 2
and Refs. 3, 5, 6, 26, 39). Our studies also highlight two major differences between the
hLHR and the rLHR. First, the t1/2 of
internalization of hCG mediated by the rLHR-wt is much slower (
120
min) than that mediated by the hLHR-wt (
20 min). We have already
shown that this difference can be fully accounted for by seven
noncontiguous residues that are not phosphorylated and are present in
topologically distinct domains (the second and third intracellular
loops and the juxtamembrane region of the C-terminal tail) of the
receptor (6). The second difference is on the effects of GRK2 on
internalization. Overexpression of this kinase shortens the
t1/2 of internalization of hCG mediated by the
rLHR-wt approximately 2-fold (39), but it has only a minimal effect on
the t1/2 of internalization of hCG mediated by
the hLHR-wt (Fig. 5
, left panel).
When considered together these results clearly show that the rLHR and
the hLHR internalize hCG by a pathway that is facilitated by
agonist-induced activation and phosphorylation of the receptor and
requires the participation of the nonvisual arrestins and dynamin. More
importantly, our ability to analyze activation, internalization, and
phosphorylation of the hLHR in transiently transfected cells (as shown
in this paper) has now allowed us to conduct more extensive
structure-function studies that provided novel mechanistic information
about the relative importance of receptor activation and
phosphorylation to the process of internalization. A summary of the
most relevant data regarding this issue is presented in Table 3
to facilitate the following discussion. The overall
importance of receptor activation and phosphorylation can be readily
documented by the finding that three distant mutations (i.e.
D405N in TM2, Y546F in TM5, and I625K in TM7) of the hLHR that impair
hCG-induced receptor activation and hCG-induced phosphorylation
lengthen the t1/2 of agonist internalization to
values (100150 min) that are close to the t1/2
of internalization of hCG mediated by the hLHR-wt in cells in which
endocytosis has been blocked with a dominant- negative mutant of
dynamin (
160 min). The results summarized in Table 3
also show that
1) phosphorylation is relatively unimportant to internalization if
activation is normal because the 5S/A mutant internalizes hCG with a
t1/2 (
30 min) that is only slightly longer
than that of hLHR-wt (
20 min); and 2) activation is relatively
unimportant to internalization if phosphorylation is normal because the
long t1/2 of internalization of hCG displayed by
the signaling-impaired mutants can be shortened to 3050 min when the
phosphorylation of these mutants is rescued by cotransfection with
GRK2. When considered together, these results are consistent with a
model whereby hCG-induced activation and phosphorylation of the hLHR
play redundant roles in internalization. Ultimately, however, it is
obvious that in the absence of phosphorylation or receptor activation,
the long t1/2 of internalization of hCG can be
readily rescued by overexpression of arrestin-3 (Table 2
). Thus, the
data presented here also document the paramount importance of the
interaction of the hLHR with a nonvisual arrestin to the process of
internalization.
View this table:
[in this window]
[in a new window]
|
Table 3. Summary of the Relative Importance of Receptor
Activation and Phosphorylation on the Agonist-Induced Internalization
of the hLHR
|
|
The large number of studies conducted with the
ß2-adrenergic receptor
(ß2-AR) have resulted in a model that
highlights the importance of the ß2-AR
phosphorylation to the process of internalization. In this model the
main role of the agonist-induced activation of the
ß2-AR is to promote the GRK-catalyzed
phosphorylation of the receptor (reviewed in Refs. 28, 29, 30). This
phosphorylation of the ß2-AR in turn enhances
the affinity of the receptor for a nonvisual arrestin leading to the
formation of a binary complex between the phosphorylated
ß2-AR and a nonvisual arrestin. Since the
nonvisual arrestins bind clathrin with high affinity, this complex
targets the receptor to clathrin-coated pits for internalization
(28, 29, 30). The results presented here indicate that the model derived
from the study of the ß2-AR is generally
applicable to the agonist-induced internalization of the hLHR. A
salient difference, however, is that, instead of highlighting the
importance of receptor phosphorylation, our data suggest that the
agonist-induced activation and phosphorylation of the hLHR play
redundant roles in internalization. In addition, recent studies
performed with other GPCRs suggest that generalizations about the
relative roles of GPCR activation and phosphorylation to the process of
internalization cannot be readily made. For example, phosphorylation of
the PTH (40) and the FSH receptors (22) seem to be less important than
activation in the process of internalization, whereas the
phosphorylation of the µ-opioid receptor seems to be more important
than activation in the process of internalization (41).
The reasons behind the ability of activating mutations of the hLHR
(L457R, D578Y, and D578H) to internalize hCG faster than hLHR-wt (Table 2
) remain elusive. As shown here these mutants cannot be further
activated or phosphorylated by hCG (Table 1
and Figs. 1
and 2
). The
involvement of receptor phosphorylation in the internalization of hCG
can still be documented by mutation of the phosphorylation sites
of these activating mutants, however (Fig. 6
). Thus, when occupied by
hCG, these three activating mutations seem to assume a conformation
that bypasses many of the requirements (i.e. activation,
phosphorylation, and/or arrestin binding) needed for the
internalization of agonist.
In summary, the studies presented herein and elsewhere (2, 3, 7, 8, 9)
show a remarkable association between the activation and the
internalization of the LHR, and the new studies presented here imply
that the activation and phosphorylation of the hLHR play redundant
roles in the process of internalization. The intimate association
between receptor activation and internalization suggests that
internalization is part of the process of activation or, conversely,
that it represents a short feedback loop involved in the termination of
hormone action. Either scenario argues for continued research to fully
understand the molecular and cellular basis of this pathway.
 |
MATERIALS AND METHODS
|
---|
Plasmids and Cells
A full-length cDNA encoding for the hLHR (42) was generously
provided by Ares Serono. Conventional PCR strategies were used to
introduce a small oligonucleotide
(5'-GAACAAAAGCTTATTTCTGAAGAAGACTTG-3') encoding the myc epitope
(EQKLISEEDL, see Ref. 43) between the predicted C terminus of the
signal peptide (Ala24) and the predicted N
terminus of the mature receptor (Leu25). This
modified receptor was subcloned into pcDNA 3.1 for expression and used
as a template for all the mutations used here. All mutants were also
constructed using standard PCR strategies, and their identity was
verified by automated DNA sequencing (performed by the DNA core of The
Diabetes and Endocrinology Research Center of the University of Iowa).
Preliminary experiments comparing the behavior of the hLHR-wt with and
without the myc epitope showed that the addition of this epitope has
little or no effect on receptor expression, hormone binding,
agonist-induced activation (as measured by cAMP accumulation), or
agonist-induced internalization of the hLHR. In addition, myc tagging
of the closely related rLHR in the equivalent location was previously
shown to have little or no effect on these properties of the rLHR
(8, 44).
Vectors encoding for GRK2 (45) arrestin-3 and arrestin-3(284409) (31)
were generously provided by Dr. Jeff Benovic (Thomas Jefferson
University, Philadelphia, PA). An expression vector for dynamin-K44A
(27) was generously provided by Dr. Sandra Schmid (Scripps Research
Institute, La Jolla, CA). All of these were subcloned into
pcDNA3.1. The expression of these constructs in our experimental system
has been previously documented (34, 39).
Human embryonic kidney (293) cells were maintained in DMEM containing
10 mM HEPES, 10% newborn calf serum, and 50 µg/ml
gentamicin, pH 7.4. Transient transfections were done using the calcium
phosphate method of Chen and Okayama (46). Cells were plated in 100-mm
dishes that had been coated with gelatin and transfected (using 5 µg
of plasmid for the 100-mm dishes or 0.2 µg of plasmid for the 35-mm
wells) when 7080% confluent. After an overnight incubation, the
cells were washed, trypsinized, and, depending on the assay to be
performed, plated in gelatin-coated dishes or wells and incubated for
an additional 24 h before use.
Binding, Internalization, and cAMP Assays
The expression of the different receptor constructs was
ascertained by measuring the binding of a saturating (13
nM) concentration of 125I-hCG (the
Kd for hCG binding to the hLHR is 13
nM; see Ref. 6) to intact cells. All binding assays were
done during a 1-h incubation at room temperature using transfected
cells plated in gelatin-coated 35-mm wells (see above). They were all
corrected for nonspecific binding, which was measured in the presence
of 50 IU/ml of partially purified hCG (3,000 IU/mg). The methods used
to measure the internalization of 125I-hCG have
been described previously (5, 26). Determinations of the rates of
internalization were done using at least five different data points
collected at 3- to 10-min intervals (depending on the construct
transfected) after the addition of a concentration of
125I-hCG (3 nM) equivalent to the
Kd. The endocytotic rate constant (ke) was
calculated from the slope of the line obtained by plotting the
internalized radioactivity against the integral of the surface-bound
radioactivity (6, 26, 47). The half-time of internalization is defined
as 0.693/ke.
Hormonal responsiveness was assessed by measuring cAMP accumulation in
intact transfected cells plated in gelatin-coated 35-mm wells (see
above). Total cAMP was measured at the end of a 2-h incubation (37 C)
in medium devoid of phosphodiesterase
inhibitors6 and supplemented with
buffer only or with concentrations of hCG (3 nM) or cholera
toxin (0.6 nM) that are known to be maximally effective in
transiently transfected cells expressing hLHR-wt (14, 48).
Dose-response curves were generated by incubating transiently
transfected cells with increasing concentrations of hCG as shown in
Fig. 1
. The parameters that describe these dose responses
(i.e. EC50 and maximal response) were
calculated from these data as described elsewhere (7, 12, 13).
Phosphorylation Assays
Cells were plated in 100-mm dishes that had been coated with
gelatin and transfected when 7080% confluent. After an overnight
incubation, the cells were washed, trypsinized, and plated in
gelatin-coated 100-mm dishes and in gelatin-coated 35-mm wells and
incubated in DMEM containing 10 mM HEPES, 1% BSA, and 50
µg/ml gentamicin, pH 7.4, for 24 h.
The cells plated in 35-mm wells were used to assess cell surface
receptor expression by 125I-hCG as described
above. The cells plated in the 100-mm dishes were used for
phosphorylation assays as follows. The medium was aspirated and the
cells were incubated for 3 h at 37 C in DMEM devoid of phosphate
but containing 10 mM HEPES, 1% BSA, 50 µg/ml gentamicin,
and 200 µCi/ml 32P-orthophosphate. At this
point the cells received buffer only, hCG (final concentration, 26
nM), or PMA (final concentration, 200 nM) and
the incubation was continued for 15 min at 37 C. These concentrations
and times were chosen based on the maximal effects of hCG and PMA on
the phosphorylation of the rLHR (1, 2, 3, 13). Cells were placed on ice
and washed once with buffer A (0.15 M NaCl, 20
mM HEPES, 5 mM EDTA, 3 mM EGTA, 50
mM ß-glycerophosphate, 10 mM NaF, 100
µM sodium orthovanadate, 1 mM phenylmethyl
sulfonyl fluoride, 1 µM leupeptin, 0.08 µg/ml okadaic
acid, 1 nM cypermethrin, and 1 µM pepstatin
A, pH 7.4). After addition of 1 ml of lysis buffer (1% NP40, 4 mg/ml
dodecyl-ß-D-maltoside. 0.8 mg/ml cholesteryl
hemisuccinate in buffer A) the dishes were rocked on ice for 30 min.
The lysate was clarified by centrifugation, and aliquots containing the
same amount of receptor (calculated from the binding experiments done
in parallel as described above) were partially purified on a wheat germ
agglutinin column as described before (37). The eluant from the wheat
germ agglutinin column was incubated with a monoclonal antibody to the
myc epitope (9E10) that had been preabsorbed to agarose-conjugated
protein G (see below) for 90120 min at 4 C. After extensive washing
the material absorbed to the beads was eluted by vigorous mixing of the
beads in SDS sample buffer for 15 min at room temperature. The eluted
material was then resolved on SDS gels, the gels were visualized and
quantitated using a PhosphorImager, and the images were captured in a
digital format for presentation.
In more recent experiments we have been able to omit the wheat germ
agglutinin column and use crude lysates for immunoprecipitation. This
protocol is less laborious and more economical but it often reveals
faint bands of a mol wt similar to that of the hLHR in the negative
controls (c.f. Fig. 4
). These are nonspecific bands, however, that can
also be detected in untransfected cells or in cells transfected with
pcDNA3.1.
Prebinding of the 9E10 antibody to the protein G agarose beads was
accomplished by incubating 50 µl of a 2025x dilution of
concentrated antibody (a concentrated supernatant from cultured 9E10
cells) with 25 µl of a 50% slurry of protein G agarose (purchased
from Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
overnight at 4 C. The beads were then washed by centrifugation and used
as described above.
Analysis of the Turnover of the Free hLHR by Surface
Biotinylation
Transfected cells plated in gelatin-coated 35-mm wells (see
above) were washed four times with ice-cold PBS (10 mM
sodium phosphate, 150 mM NaCl, pH 8) and then biotinylated
during two consecutive 15 min incubations (at room temperature) with
freshly prepared 0.5 mg/ml solutions of
sulfosuccinimidyl-6-(biotinamido)hexanoate (from Vector Laboratories, Inc., Burlingame, CA) in the same buffer. The
cells were then washed once with DMEM containing 10 mM
HEPES, 10% newborn calf serum, and 50 µg/ml gentamicin, pH 7.4, and
twice with PBS (35, 36). Some cells were saved on ice and processed
immediately (t = 0 samples), while others were incubated in warm
DMEM containing 10 mM HEPES, 10% newborn calf serum, and
50 µg/ml gentamicin, pH 7.4, for 4 h. At the indicated times the
cells were placed on ice, lysed, and immunoprecipitated with the 9E10
antibody prebound to protein G agarose. Lysates and
immunoprecipitations were prepared as described in
Phosphorylation Assays, except that okadaic acid and
cypermethrin were not included in the solutions and the lysates were
not purified on wheat germ agglutinin before immunoprecipitation. Also,
no attempt was made to normalize the amount of receptor
immunoprecipitated among the different constructs used. The
immunoprecipitates were resolved on SDS gels as described above, and
the resolved proteins were electrophoretically transferred to
polyvinylidene fluoride membranes as described elsewhere (49).
After blocking (49), the blots were incubated for 1 h with 100
ng/ml of horse-radish peroxidase-conjugated streptavidin (from
Vector Laboratories, Inc.), and the proteins were finally
visualized using the Super Signal West Femto Maximum Sensitivity system
of detection from Pierce Chemical Co. (Madison, WI). The
blots were visualized and quantitated using a Fluo-S MAX system
(Bio-Rad Laboratories, Inc., Hercules, CA). These images
were also captured in a digital format for presentation (c.f. Fig. 7
).
Hormones and Supplies
Human embryonic kidney (293) cells and the 9E10 hybridoma cell
line were obtained from the American Type Culture Collection (Manassas, VA). Purified hCG (CR-127,
13,000
IU/mg) was kindly provided by Dr. A. Parlow and the National Hormone
and Pituitary Agency of the National Institute of Diabetes and
Digestive and Kidney Diseases. 125I-hCG was
prepared as described elsewhere (50). Partially purified hCG (
3,000
IU/mg) was purchased from Sigma (St. Louis, MO), and it
was used only for the determination of nonspecific binding (see above).
125I-cAMP and cell culture medium were obtained
from the Iodination Core and the Media and Cell Production Core,
respectively, of the Diabetes and Endocrinology Research Center of the
University of Iowa. Concentrated supernatant from the 9E10 cells was
prepared by the Hybridoma Facility of the Cancer Center of the
University of Iowa. Other cell culture supplies and reagents were
obtained from Corning, Inc. (Corning, NY) and Life Technologies, Inc. (Gaithersburg, MD), respectively. All other
chemicals were obtained from commonly used suppliers.
 |
ACKNOWLEDGMENTS
|
---|
We thank Drs. Kazuto Nakamura and Xuebo Liu for suggestions with
different technical aspects of this project. We also wish to thank Dr.
Jeffrey Benovic (Thomas Jefferson University, Philadelphia, PA) and Dr.
Sandra Schmid (Scripps Research Institute, La Jolla, CA) for reagents
and Dr. Deborah Segaloff (University of Iowa College of Medicine, Iowa
City, IA) for critically reading this manuscript.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Dr. Mario Ascoli, Department of Pharmacology, The University of Iowa 2319B BSB, 51 Newton Road, Iowa City, IA 52242-1109. E-mail: mario-ascoli{at}uiowa.edu
This work was supported by a grant from the NIH: CA-40629 to MA. The
services and facilities provided by the Diabetes and Endocrinology
Research Center of the University of Iowa were supported by NIH grant
DK-25295.
1 Note that the mature rLHR and hLHR highly
homologous proteins are composed of 674 and 677 residues, respectively
(23 ). The different numbers assigned to equivalent residues are
artificially caused by differences in the numbering of amino acids.
Since the N terminus of the mature hLHR is not known, residue number 1
is taken to be the methionine present at the N terminus of the signal
peptide. In contrast, since the N terminus of the mature rLHR is known,
this residue (which corresponds to residue 23 of the hLHR) is taken to
be residue number 1. 
2 Note that although we use cAMP as a measurement
of receptor activation we do not imply that cAMP per se
is necessary for internalization. In fact, a role for cAMP in this
process has already been excluded (32 ). 
3 In agreement with previous results (22 33 34 ),
we found that GRK2 cotransfections did not enhance receptor
phosphorylation in cells incubated without hCG. 
4 Mutation of the phosphorylation sites of the
activating or inactivating mutations of the hLHR had little or no
effect on their signaling properties (not shown). 
5 As noted above, the low level of expression of
the I625K mutant made it difficult to reliably measure phosphorylation.
Throughout the rest of this paper we assume that the properties of the
phosphorylation of the I625K mutant are similar to those of the D405N
and Y546F mutants. 
6 Experiments performed in medium with
isobutylmethylxanthine (a phosphodiesterase inhibitor) gave
qualitatively similar results. 
Received for publication June 7, 2000.
Revision received July 25, 2000.
Accepted for publication August 11, 2000.
 |
REFERENCES
|
---|
-
Hipkin RW, Sánchez-Yagüe J, Ascoli M 1993 Agonist-induced phosphorylation of the luteinizing hormone/chorionic
gonadotropin (LH/CG) receptor expressed in a stably transfected cell
line. Mol Endocrinol 7:823832[Abstract]
-
Wang Z, Liu X, Ascoli M 1997 Phosphorylation of the
lutropin/choriogonadotropin receptor facilitates uncoupling of the
receptor from adenylyl cyclase and endocytosis of the bound hormone.
Mol Endocrinol 11:183192[Abstract/Free Full Text]
-
Lazari MFM, Bertrand JE, Nakamura K, Liu X, Krupnick JG,
Benovic JL, Ascoli M 1998 Mutation of individual serine residues in the
C-terminal tail of the lutropin/choriogonadotropin (LH/CG) receptor
reveal distinct structural requirements for agonist-induced uncoupling
and agonist-induced internalization. J Biol Chem 273:1831618324[Abstract/Free Full Text]
-
Ghinea N, Vuhai MT, Groyer-Picard M-T, Houllier A,
Schoëvaërt D, Milgrom E 1992 Pathways of internalization of
the hCG/LH receptor: immunoelectron microscopic studies in Leydig cells
and transfected L cells. J Cell Biol 118:13471358[Abstract]
-
Nakamura K, Ascoli M 1999 A dileucine-based motif in the
C-terminal tail of the lutropin/choriogonadotropin receptor inhibits
endocytosis of the agonist-receptor complex. Mol Pharmacol 56:728736[Abstract/Free Full Text]
-
Nakamura K, Liu X, Ascoli M 2000 Seven non-contiguous
intracellular residues of the lutropin/choriogonadotropin receptor
dictate the rate of agonist-induced internalization, its sensitivity to
non-visual arrestins. J Biol Chem 275:241247[Abstract/Free Full Text]
-
Dhanwada KR, Vijapurkar U, Ascoli M 1996 Two mutations of the
lutropin/choriogonadotropin receptor that impair signal transduction
also interfere with receptor-mediated endocytosis. Mol Endocrinol 10:544554[Abstract]
-
Min K-S, Liu X, Fabritz J, Jaquette J, Abell AN, Ascoli M 1998 Mutations that induce constitutive activation and mutations that
impair signal transduction modulate the basal and/or agonist-stimulated
internalization of the lutropin/choriogonadotropin receptor. J
Biol Chem 273:3491134919[Abstract/Free Full Text]
-
Bradbury FA, Menon KMJ 1999 Evidence that constitutively
active luteinizing hormone/human chorionic gonadotropin receptors are
rapidly internalized. Biochemistry 38:87038712[CrossRef][Medline]
-
Freedman N, Lefkowitz R 1996 Desensitization of G
protein-coupled receptors. Recent Prog Horm Res 51:319353[Medline]
-
Pitcher JA, Freedman NJ, Lefkowitz RJ 1998 G protein-coupled
receptor kinases. Annu Rev Biochem 67:653692[CrossRef][Medline]
-
Hipkin RW, Wang Z, Ascoli M 1995 Human chorionic gonadotropin-
and phorbol ester stimulated phosphorylation of the LH/CG receptor maps
to serines 635, 639, 645 and 652 in the C-terminal cytoplasmic tail.
Mol Endocrinol 9:151158[Abstract]
-
Wang Z, Hipkin RW, Ascoli M 1996 Progressive cytoplasmic
tail truncations of the lutropin-choriogonadotropin receptor
prevent agonist- or phorbol ester-induced phosphorylation, impair
agonist- or phorbol ester-induced desensitization and enhance
agonist-induced receptor down-regulation. Mol Endocrinol 10:748759[Abstract]
-
Latronico AC, Abell AN, Arnhold IJP, Liu X, Lins TSS, Brito
VN, Bilerbeck AE, Segaloff DL, Mendonica BB 1998 A unique
constitutively activating mutation in third transmembrane helix of
luteinizing hormone receptor causes sporadic male
gonadotropin-independent precocious puberty. J Clin Endocrinol
Metab 83:24352440[Abstract/Free Full Text]
-
Laue L, Chan W-Y, Hsueh AJW, Kudo M, Hsu SY, Wu S-M, Blomberg
L, Cutler J, GB 1995 Genetic heterogeneity of constitutively activating
mutations of the human luteinizing hormone receptor in familial
male-limited precocious puberty. Proc Natl Acad Sci USA 92:19061910[Abstract]
-
Liu G, Duranteau L, Carel J-C, Monroe J, Doyle DA, Shenker A 1999 Leydig-cell tumors caused by an activating mutation of the gene
encoding the luteinizing hormone receptor. N Engl J Med 341:17311736[Free Full Text]
-
Kosugi S, Mori T, Shenker A 1996 The role of
Asp578 in maintaining the inactive conformation
of the human lutropin/choriogonadotropin receptor. J Biol Chem 271:3181331817[Abstract/Free Full Text]
-
Martens JWM, Verhoef-Post M, Abelin N, Ezabella M, Toledo SPA,
Brunner HG, Themmen APN 1998 A homozygous mutation in the luteinizing
hormone receptor causes partial Leydig cell hypoplasia: correlation
between receptor activity and phenotype. Mol Endocrinol 12:775784[Abstract/Free Full Text]
-
Ceresa BP, Limbird LE 1994 Mutation of an aspartate residue
highly conserved among G-protein coupled receptors results in
non-reciprocal disruption of
2-adrenergic receptor-G protein
interactions. J Biol Chem 269:2955729564[Abstract/Free Full Text]
-
Hunyady L, Bor M, Balla T, Catt KJ 1995 Critical role of
a conserved intramembrane tyrosine residue in angiotensin II receptor
activation. J Biol Chem 270:97029705[Abstract/Free Full Text]
-
Quintana J, Wang H, Ascoli M 1993 The regulation of the
binding affinity of the luteinizing hormone/choriogonadotropin receptor
by sodium ions is mediated by a highly conserved aspartate located in
the second transmembrane domain of G protein-coupled receptors. Mol
Endocrinol 7:767775[Abstract]
-
Nakamura K, Krupnick JG, Benovic JL, Ascoli M 1998 Signaling
and phosphorylation-impaired mutants of the rat follitropin receptor
reveal and activation- and phosphorylation-independent but
arrestin-dependent pathway for internalization. J Biol Chem 273:2434624354[Abstract/Free Full Text]
-
Segaloff DL, Ascoli M 1993 The lutropin/choriogonadotropin
(LH/CG) receptor ... 4 years later. Endocr Rev 14:324347[Abstract]
-
Mhaouty-Kodja S, Barak LS, Scheer A, Abuin L, Diviani D, Caron
MG, Cotecchia S 1999 Constitutively active
-1b adrenergic receptor
mutants display different phosphorylation and internalization features.
Mol Pharmacol 55:339347[Abstract/Free Full Text]
-
Thomas WG, Qian H, Chang C-S, Karnik S 2000 Agonist-induced
phosphorylation of the angiotensin II (AT1A) receptor requires
generation of a conformation that is distinct from the inositol
phosphate-signaling state. J Biol Chem 275:28932900[Abstract/Free Full Text]
-
Nakamura K, Liu X, Ascoli M 1999 The rate of internalization
of the gonadotropin receptors is greatly affected by the origin of the
extracellular domain. J Biol Chem 274:2542625432[Abstract/Free Full Text]
-
Damke H, Baba T, Warnock DE, Schmid SL 1994 Induction of
mutant dynamin specifically blocks endocytic coated vesicle formation.
J Cell Biol 127:915934[Abstract]
-
Lefkowitz RJ 1998 G protein-coupled receptors. III. New roles
for receptor kinases and ß-arrestins in receptor signaling and
desensitization. J Biol Chem 273:1867718680[Free Full Text]
-
Ferguson SS, Caron MG 1998 G protein-coupled receptor
adaptation mechanisms. Semin Cell Dev Biol 9:119127[CrossRef][Medline]
-
Carman CV, Benovic JL 1998 G-protein-coupled receptors:
turn-ons and turn-offs. Curr Opin Neurobiol 8:335344[CrossRef][Medline]
-
Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL 1997 Modulation of the arrestin-clathrin interaction in cells. J Biol
Chem 272:3250732512[Abstract/Free Full Text]
-
Hoelscher SR, Sairam MR, Ascoli M 1991 The slow rate of
internalization of deglycosylated hCG is not due to its inability to
stimulate cAMP accumulation. Endocrinology 128:28372843[Abstract]
-
Ferguson SSG, Menard L, Barak LS, Koch WJ, Colapietro A-M,
Caron MG 1995 Role of phosphorylation in agonist-promoted
ß2-adrenergic receptor sequestration. J Biol Chem 270:2478224789[Abstract/Free Full Text]
-
Lazari MFM, Liu X, Nakamura K, Benovic JL, Ascoli M 1999 Role
of G protein-coupled receptor kinases on the agonist-induced
phosphorylation, and internalization of the follitropin receptor. Mol
Endocrinol 13:866878[Abstract/Free Full Text]
-
Altin JG, Pagler EB 1995 A one-step procedure for
biotinylation and chemical cross-linking of lymphocyte surface and
intracellular membrane-associated molecules. Anal Biochem 224:382389[CrossRef][Medline]
-
Huang Z, Bambino T, Chen Y, Lameh J, Nissenson RA 1999 Role of
signal transduction in internalization of the G protein-coupled
receptor for parathyroid hormone (PTH) and PTH-related protein.
Endocrinology 140:12941300[Abstract/Free Full Text]
-
Hipkin RW, Sánchez-Yagüe J, Ascoli M 1992 Identification and characterization of a luteinizing hormone/chorionic
gonadotropin (LH/CG) receptor precursor in a human kidney cell line
stably transfected with the rat luteal LH/CG receptor complementary
DNA. Mol Endocrinol 6:22102218[Abstract]
-
VuHai-LuuThi MT, Misrahi M, Houillier A, Jolivet A, Milgrom E 1992 Variant forms of the pig lutropin/choriogonadotropin receptor.
Biochemistry 31:83778383[Medline]
-
Nakamura K, Lazari MFM, Li S, Korgaonkar C, Ascoli M 1999 Role
of the rate of internalization of the agonist-receptor complex on the
agonist-induced down-regulation of the lutropin/choriogonadotropin
receptor. Mol Endocrinol 13:12951304[Abstract/Free Full Text]
-
Malecz N, Bambino T, Bencsik M, Nissenson RA 1998 Identification of phosphorylation sites in the G protein-coupled
receptor for parathyroid hormone. Receptor phosphorylation is not
required for agonist-induced internalization. Mol Endocrinol 12:18461856[Abstract/Free Full Text]
-
Zhang J, Ferguson SSG, Barak LS, Bodduluri SR, Laporte SA, Law
P-Y, Caron MG 1998 Role for G protein-coupled receptor kinase in
agonist-specific regulation of µ-opioid receptor
responsiveness. Proc Natl Acad Sci USA 95:71577162[Abstract/Free Full Text]
-
Minegishi T, Nakamura K, Takakura Y, Miyamoto K, Hasegawa Y,
Ibuki Y, Igarashi M 1990 Cloning and sequencing of human LH/hCG
receptor cDNA. Biochem Biophys Res Commun 172:10491054[Medline]
-
Evan GI, Lewis GK, Ramsey G, Bishop MJ 1985 Isolation of
momoclonal antibodies specific for human c-myc proto-oncogene product.
Mol Cell Biol 5:36103616[Medline]
-
Fabritz J, Ryan S, Ascoli M 1998 Transfected cells express
mostly the intracellular precursor of the lutropin/choriogonadotropin
receptor but this precursor binds choriogonadotropin with high
affinity. Biochemistry 37:664672[CrossRef][Medline]
-
Benovic JL, DeBlasi A, Stone CW, Caron MG, Lefkowitz RJ 1989 ß-adrenergic receptor kinase: primary structure delineates
a multigene family. Science 246:235240[Medline]
-
Chen C, Okayama H 1987 High-efficiency transformation of
mammalian cells by plasmid DNA. Mol Cell Biol 7:27452752[Medline]
-
Wiley HS, Cunningham DD 1982 The endocytotic rate constant. A
cellular parameter for quantitating receptor-mediated endocytosis.
J Biol Chem 257:42224229[Free Full Text]
-
Latronico AC, Chai Y, Arnhold IJP, Liu X, Mendonca BB,
Segaloff DL 1998 A homozygous microdeletion in helix 7 of the
luteinizing hormone receptor associated with familial testicular and
ovarian resistance is due to both decreased cell surface expression and
impaired effector activation by the cell surface receptor. Mol
Endocrinol 12:442450[Abstract/Free Full Text]
-
Quintana J, Hipkin RW, Ascoli M 1993 A polyclonal antibody to
a synthetic peptide derived from the rat FSH receptor reveals the
recombinant receptor as a 74 kDa protein. Endocrinology 133:20982104[Abstract]
-
Ascoli M, Puett D 1978 Gonadotropin binding and stimulation of
steroidogenesis in Leydig tumor cells. Proc Natl Acad Sci USA 75:99102[Abstract]